These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25148100)

  • 1. Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025).
    Ivachtchenko AV; Mitkin OD; Yamanushkin PM; Kuznetsova IV; Bulanova EA; Shevkun NA; Koryakova AG; Karapetian RN; Bichko VV; Trifelenkov AS; Kravchenko DV; Vostokova NV; Veselov MS; Chufarova NV; Ivanenkov YA
    J Med Chem; 2014 Sep; 57(18):7716-30. PubMed ID: 25148100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors.
    Ivashchenko AA; Ivanenkov YA; Aladinskiy VA; Karapetian RN; Koryakova AG; Ryakhovskiy AA; Mitkin OD; Kravchenko DV; Savchuk NP; Zagribelnyy BA; Ivashchenko AV
    Bioorg Med Chem; 2020 Oct; 28(20):115716. PubMed ID: 33069072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.
    Coburn CA; Meinke PT; Chang W; Fandozzi CM; Graham DJ; Hu B; Huang Q; Kargman S; Kozlowski J; Liu R; McCauley JA; Nomeir AA; Soll RM; Vacca JP; Wang D; Wu H; Zhong B; Olsen DB; Ludmerer SW
    ChemMedChem; 2013 Dec; 8(12):1930-40. PubMed ID: 24127258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.
    Boucle S; Tao S; Amblard F; Stanton RA; Nettles JH; Li C; McBrayer TR; Whitaker T; Coats SJ; Schinazi RF
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3711-5. PubMed ID: 26099532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.
    Belema M; Nguyen VN; Bachand C; Deon DH; Goodrich JT; James CA; Lavoie R; Lopez OD; Martel A; Romine JL; Ruediger EH; Snyder LB; St Laurent DR; Yang F; Zhu J; Wong HS; Langley DR; Adams SP; Cantor GH; Chimalakonda A; Fura A; Johnson BM; Knipe JO; Parker DD; Santone KS; Fridell RA; Lemm JA; O'Boyle DR; Colonno RJ; Gao M; Meanwell NA; Hamann LG
    J Med Chem; 2014 Mar; 57(5):2013-32. PubMed ID: 24521299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 1.
    Tran TD; Wakenhut F; Pickford C; Shaw S; Westby M; Smith-Burchnell C; Watson L; Paradowski M; Milbank J; Brimage RA; Halstead R; Glen R; Wilson CP; Adam F; Hay D; Chiva JY; Nichols C; Blakemore DC; Gardner I; Dayal S; Pike A; Webster R; Pryde DC
    ChemMedChem; 2014 Jul; 9(7):1378-86. PubMed ID: 24729513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of fluorobenzimidazole HCV NS5A inhibitors.
    Randolph JT; Flentge CA; Donner P; Rockway TW; Patel SV; Nelson L; Hutchinson DK; Mondal R; Mistry N; Reisch T; Dekhtyar T; Krishnan P; Pilot-Matias T; Stolarik DF; Beno DWA; Wagner R; Maring C; Kati WM
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5462-5467. PubMed ID: 27780635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
    Gao M; Nettles RE; Belema M; Snyder LB; Nguyen VN; Fridell RA; Serrano-Wu MH; Langley DR; Sun JH; O'Boyle DR; Lemm JA; Wang C; Knipe JO; Chien C; Colonno RJ; Grasela DM; Meanwell NA; Hamann LG
    Nature; 2010 May; 465(7294):96-100. PubMed ID: 20410884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
    Amblard F; Zhang H; Zhou L; Shi J; Bobeck DR; Nettles JH; Chavre S; McBrayer TR; Tharnish P; Whitaker T; Coats SJ; Schinazi RF
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2031-4. PubMed ID: 23466233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
    Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
    Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor.
    Zhong M; Peng E; Huang N; Huang Q; Huq A; Lau M; Colonno R; Li L
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4508-4512. PubMed ID: 27506559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors.
    Zhong M; Peng E; Huang N; Huang Q; Huq A; Lau M; Colonno R; Li L
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5731-5737. PubMed ID: 25453810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons.
    Belema M; Nguyen VN; Romine JL; St Laurent DR; Lopez OD; Goodrich JT; Nower PT; O'Boyle DR; Lemm JA; Fridell RA; Gao M; Fang H; Krause RG; Wang YK; Oliver AJ; Good AC; Knipe JO; Meanwell NA; Snyder LB
    J Med Chem; 2014 Mar; 57(5):1995-2012. PubMed ID: 24437689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
    Wang C; Jia L; Huang H; Qiu D; Valera L; Huang X; Sun JH; Nower PT; O'Boyle DR; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1588-90. PubMed ID: 22203595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Potent, Selective, and Orally Bioavailable HCV NS5A Inhibitor for Treatment of Hepatitis C Virus: (S)-1-((R)-2-(Cyclopropanecarboxamido)-2-phenylacetyl)-N-(4-phenylthiazol-2-yl)pyrrolidine-2-carboxamide.
    Kang IJ; Hsu SJ; Yang HY; Yeh TK; Lee CC; Lee YC; Tian YW; Song JS; Hsu TA; Chao YS; Yueh A; Chern JH
    J Med Chem; 2017 Jan; 60(1):228-247. PubMed ID: 27966956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
    Yang H; Robinson M; Corsa AC; Peng B; Cheng G; Tian Y; Wang Y; Pakdaman R; Shen M; Qi X; Mo H; Tay C; Krawczyk S; Sheng XC; Kim CU; Yang C; Delaney WE
    Antimicrob Agents Chemother; 2014; 58(2):647-53. PubMed ID: 23939899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus.
    Yeh TK; Kang IJ; Hsu TA; Lee YC; Lee CC; Hsu SJ; Tian YW; Yang HY; Chen CT; Chao YS; Yueh A; Chern JH
    Eur J Med Chem; 2019 Apr; 167():245-268. PubMed ID: 30772607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.